Prognóstico em dois anos do câncer de cavidade oral

2007 
Introducao: realizamos um estudo transversal retrospectivo, no qual foram revisados os prontuarios medicos dos pacientes com câncer de cavidade oral. Objetivo: tracar o perfil onco-epidemiologico desses pacientes, bem como comparar a sobrevida em dois anos do Dutch Group (software OncologIQ®) com a nossa. Pacientes e Metodo: a nossa amostra foi composta de 39 pacientes, sendo 38 do genero masculino e um do feminino, com media de idade, na primeira consulta, de 54 anos. Fizemos uso do software OncologIQ®, para estimativa de sobrevida. Resultados: o estadio IV representou 41% dos pacientes, seguido do estadio III, com 33%. Apenas 10% dos pacientes pertenciam ao estadio I. De acordo com o T-stage, T2 aparece com 43% dos pacientes enquanto T4 com 28%. O T-stage T1 surge apenas com 10% dos pacientes. Esse estudo expressou uma sobrevida em dois anos de 100% dos pacientes presentes nos estadios I e II, de 69% no estadio III, enquanto que, no estadio IV, expos uma sobrevida em dois anos de 37,5% dos pacientes. Os mesmos pacientes foram avaliados pelo software OncologIQ® e a sobrevida estimada em dois anos foi, respectivamente, de 82% e 73% para os estadios I e II. O estadio III teve uma sobrevida estimada de 57%, ao passo que, para o estadio IV, a sobrevida em dois anos estimada foi de 45%. A media geral da sobrevida em 02 anos, independente do estadiamento, foi de 76%. Conclusao: a sobrevida em dois anos dos nossos pacientes foi compativel com dados do software OncologIQ®, no aspecto geral e especifico por estadio. Introduction: we performed a retrospective transversal study, in which the medical charts of patients with oral cavity cancer were analyzed. Objective: to obtain an onco-epidemiolological profile of the patients involved, as well as to compare the two-year survival rate of the Dutch Group (OncologIQ® software) with that of our group. Materials and methods: our sample was composed by 39 patients, 38 being men and 1 woman, with an average age of 54 years old at the time of the first medical visit. An estimative of the survival rate was performed with the aid of OncologIQ® software. Results: Stage IV represented 41% of the patients, followed by stage III with 33%. Only 10% of the patients were at stage I. According to the T-stage, T2 appears with 43% of patients, whereas T4 presented 28%. T-stage T1 appears in 10% of the patients. This study expressed a 2 years survival rate of 100% of the patients in stages I and II, a rate of 69% in patients in stage III, and a rate of 37.5% in patients in stage IV. The same patients were assessed using the OncologIQ® software, and the estimated survival rate in two years was 82% and 73% for stages I and II respectively. Stage III had an estimated survival rate of 57%, while that of stage IV was estimated at 45%. The average survival rate at 2 years, independent of the stage, was 76%. Conclusion: the survival rate of our patients was compatible with the data from the OncologIQ® software, in relation to the general aspect and specifically in relation to the stages.
    • Correction
    • Cite
    • Save
    • Machine Reading By IdeaReader
    7
    References
    3
    Citations
    NaN
    KQI
    []